NTLA
HealthcareIntellia Therapeutics, Inc. · Biotechnology · $1B
What is Intellia Therapeutics, Inc.?
Intellia Therapeutics is a clinical-stage genome editing company developing CRISPR/Cas9-based therapies for serious genetic diseases. It operates from Cambridge, Massachusetts.
Intellia advances two types of programs: in vivo therapies that edit genes directly inside the body, and ex vivo cell therapies engineered outside the body before infusion. Revenue comes primarily from collaboration agreements with partners such as Regeneron and Novartis rather than product sales, as no therapies have yet reached commercial approval.
Intellia was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
- NTLA-2001 — in vivo program for transthyretin amyloidosis (Phase 1)
- NTLA-2002 — in vivo program for hereditary angioedema
- NTLA-5001 — ex vivo cell therapy for acute myeloid leukemia
- CRISPR/Cas9 platform licensed to partners for sickle cell disease and ocular diseases
Is NTLA a Good Stock to Buy?
UQS Score rates NTLA as Below Average overall.
The Growth and Risk pillars both carry Good ratings, reflecting a pipeline with multiple active clinical programs and a risk profile that is not extreme for a clinical-stage biotech. These are the clearest relative strengths in the current UQS assessment.
Quality and Moat both register as Weak, and Valuation is Elevated — a combination that signals the market is pricing in significant future success that has yet to materialize.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does NTLA pay dividends?
No — Intellia Therapeutics, Inc. does not currently pay a dividend.
Intellia does not pay a dividend. As a clinical-stage company with no approved products, available capital is directed toward research, clinical trials, and platform development rather than shareholder distributions.
When does NTLA report earnings?
Intellia Therapeutics reports earnings on a quarterly cadence, typical for US-listed equities.
Results in recent quarters have reflected the realities of a pre-revenue biotech — operating expenses driven by clinical activity and collaboration income providing partial offset. Pipeline milestones tend to move the stock more than headline financial figures.
For the most recent quarter's results, visit Intellia Therapeutics' investor relations page.
NTLA Price History
-79.6% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Intellia Therapeutics, Inc.?
Based on Intellia Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Intellia Therapeutics do?
Intellia Therapeutics develops CRISPR/Cas9-based gene editing therapies for genetic diseases. Its pipeline spans in vivo programs — editing genes inside the patient's body — and ex vivo cell therapies. The company also licenses its platform technology to partners including Regeneron and Novartis.
Does NTLA pay dividends?
No. Intellia does not pay a dividend. As a clinical-stage biotech with no commercially approved products, the company reinvests available resources into its research pipeline and clinical programs.
When does NTLA report earnings?
Intellia reports on a standard quarterly schedule. Because specific upcoming dates are subject to change, check the company's investor relations page for the most current earnings calendar.
Is NTLA a good stock to buy?
UQS Score rates NTLA as Below Average. Growth and Risk pillars are Good, but Quality and Moat are Weak and Valuation is Elevated. Whether that profile fits your portfolio depends on your risk tolerance and investment horizon. The full pillar breakdown is available to Pro members.
Is NTLA overvalued?
The UQS Valuation pillar for NTLA is rated Elevated, suggesting the current price reflects optimistic assumptions about future clinical and commercial success. Investors should weigh that against the early-stage nature of the pipeline.
What is NTLA's market cap bracket?
Intellia Therapeutics is classified as a small-cap stock. This places it in a bracket where liquidity and volatility can differ meaningfully from larger, more established healthcare companies.
Is NTLA a long-term quality investment?
From a long-term quality standpoint, the UQS framework currently rates NTLA as Below Average, with Weak scores on Quality and Moat. The Growth pillar is Good, reflecting pipeline optionality, but durable competitive advantages have not yet been established. Pro members can view the complete analysis.
What sector does NTLA belong to?
Intellia Therapeutics operates in the Healthcare sector, specifically within the biotechnology industry. It focuses on gene editing as a therapeutic modality, a sub-segment that carries both high scientific promise and significant development risk.
Unlock Full NTLA Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access full financial metrics and trend data
- ✓Compare NTLA against sector peers on every pillar
- ✓Get the complete analyst-style quality breakdown
Pro Analysis
NTLA — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | 33.1 | 2.5 | 28.0 | 72.1 | 73.9 | 0.0 | — |
NTLA — Pillar Breakdown
Quality
— 2.5/100 (25%)Intellia Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 72.1/100 (20%)Intellia Therapeutics, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 74.0/100 (15%)Intellia Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Intellia Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 28/100 (25%)Intellia Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for NTLA.
Score Composition
Financial Data
More Stock Analysis
How is the NTLA UQS Score Calculated?
The UQS (Unified Quality Score) for Intellia Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Intellia Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Intellia Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.